Amendment No. 1 to Schedule 13D for NovaBay Pharmaceuticals, Inc.

This Amendment No. 1 to Schedule 13D, filed by Framework Ventures IV L.P. and other reporting persons, updates the ownership details of NovaBay Pharmaceuticals, Inc. The amendment reports the convertibility of the Series D Non-Voting Convertible Preferred Stock following stockholder approval and the issuance of 134,375 shares of Series E Preferred Stock, which are convertible into 21,500,000 shares of Common Stock. The reporting persons collectively own 56,806,080 shares of Common Stock, representing approximately 45.1% of the outstanding shares. The amendment also includes details of a pre-funded warrant contract entered into on October 15, 2025, allowing the purchase of 2,702,703 shares of Common Stock, exercisable starting January 1, 2026, pending stockholder approval.